The ORR of nivolumab monotherapy was reported to be 11.2% in gastric cancer and 17.2% in oesophageal cancer, which corresponds to 11.8% and 18.3% of patients characterised as CRP-spike in this study. Here, CRP is linked to gastric cancer.